Rose bengal sodium

Drug Profile

Rose bengal sodium

Alternative Names: PH-10; Provecta; PV-10; Rose bengal; Rose bengal disodium; Rose bengal sodium I 125; Rose bengal sodium I 131; Xantryl

Latest Information Update: 24 Apr 2017

Price : $50

At a glance

  • Originator Photogen Technologies Inc.
  • Developer Pediatric Oncology Experimental Therapeutics Investigators Consortium; Provectus Biopharmaceuticals
  • Class Antineoplastics; Antipsoriatics; Antivirals; Fluoresceins; Small molecules
  • Mechanism of Action Cell death stimulants; Cell membrane modulators; Dendritic cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Cancer; Psoriasis

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Atopic dermatitis; Psoriasis
  • Phase I Breast cancer; Hepatocellular carcinoma; Liver metastases; Neuroendocrine tumours
  • Preclinical Acne vulgaris
  • Research Cancer

Most Recent Events

  • 08 Dec 2016 Early research in Cancer (In adolescents, In children, In infants, In neonates) in USA (Parenteral, Injection)
  • 08 Dec 2016 Provectus Biopharmaceuticals and Pediatric Oncology Experimental Therapeutics Investigators Consortium agree to co-develop Rose Bengal sodium (PV 10) for Cancer (In paediatrics)
  • 18 Jul 2016 Provectus Biopharmaceuticals receives patent allowance for the process for synthesizing halogenated xanthenes in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top